De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Dr. Sulaiman Al Habib Medical Services Group Toekomstige groei
Future criteriumcontroles 4/6
Dr. Sulaiman Al Habib Medical Services Group zal naar verwachting groeien in winst en omzet met respectievelijk 14.9% en 14.6% per jaar. De winst per aandeel zal naar verwachting groeien met 14.6% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 39.1% zijn.
Belangrijke informatie
14.9%
Groei van de winst
14.6%
Groei van de winst per aandeel
| Healthcare winstgroei | 14.9% |
| Inkomstengroei | 14.6% |
| Toekomstig rendement op eigen vermogen | 39.1% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 01 Oct 2024 |
Recente toekomstige groei-updates
Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
May 03
Earnings Beat: Dr. Sulaiman Al Habib Medical Services Group Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 27Recent updates
Investors Will Want Dr. Sulaiman Al Habib Medical Services Group's (TADAWUL:4013) Growth In ROCE To Persist
Jul 04Dr. Sulaiman Al Habib Medical Services Group's (TADAWUL:4013) Shareholders Will Receive A Bigger Dividend Than Last Year
May 23Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
May 08Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
May 03Subdued Growth No Barrier To Dr. Sulaiman Al Habib Medical Services Group Company's (TADAWUL:4013) Price
Apr 29There's Been No Shortage Of Growth Recently For Dr. Sulaiman Al Habib Medical Services Group's (TADAWUL:4013) Returns On Capital
Mar 15Dr. Sulaiman Al Habib Medical Services Group's (TADAWUL:4013) Dividend Will Be SAR1.15
Feb 22With EPS Growth And More, Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Makes An Interesting Case
Feb 20Dr. Sulaiman Al Habib Medical Services Group Company's (TADAWUL:4013) Price Is Out Of Tune With Earnings
Jan 09We Like These Underlying Return On Capital Trends At Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013)
Nov 28We Think That There Are Issues Underlying Dr. Sulaiman Al Habib Medical Services Group's (TADAWUL:4013) Earnings
Nov 07Dr. Sulaiman Al Habib Medical Services Group's (TADAWUL:4013) Shareholders Will Receive A Bigger Dividend Than Last Year
Nov 02Here's Why Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Has Caught The Eye Of Investors
Sep 21Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Is Doing The Right Things To Multiply Its Share Price
Aug 10Here's Why We Think Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Is Well Worth Watching
Jun 17Dr. Sulaiman Al Habib Medical Services Group's (TADAWUL:4013) Shareholders Will Receive A Bigger Dividend Than Last Year
May 12Returns At Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Are On The Way Up
May 06Here's Why We Think Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Might Deserve Your Attention Today
Mar 13Dr. Sulaiman Al Habib Medical Services Group's (TADAWUL:4013) Returns On Capital Are Heading Higher
Jan 30With EPS Growth And More, Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Makes An Interesting Case
Dec 07Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Is Doing The Right Things To Multiply Its Share Price
Oct 23If EPS Growth Is Important To You, Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Presents An Opportunity
Sep 08Estimating The Intrinsic Value Of Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013)
Aug 24Why Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013) Could Be Worth Watching
Aug 08Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Has More To Do To Multiply In Value Going Forward
Jul 12Does Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Deserve A Spot On Your Watchlist?
May 31A Look At The Fair Value Of Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013)
May 17Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Will Pay A Larger Dividend Than Last Year At ر.س0.83
Apr 28Should You Think About Buying Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013) Now?
Apr 09Return Trends At Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Aren't Appealing
Mar 06Here's Why I Think Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Is An Interesting Stock
Feb 16Returns On Capital At Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Have Stalled
Dec 05Do Dr. Sulaiman Al Habib Medical Services Group's (TADAWUL:4013) Earnings Warrant Your Attention?
Nov 17Investors Could Be Concerned With Dr. Sulaiman Al Habib Medical Services Group's (TADAWUL:4013) Returns On Capital
Aug 30Here's Why I Think Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Might Deserve Your Attention Today
Aug 01Estimating The Fair Value Of Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013)
Jun 11Capital Allocation Trends At Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Aren't Ideal
May 27Earnings Beat: Dr. Sulaiman Al Habib Medical Services Group Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 27Here's Why I Think Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Might Deserve Your Attention Today
Apr 06A Look At The Fair Value Of Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013)
Feb 04Is Dr. Sulaiman Al Habib Medical Services Group Company's (TADAWUL:4013) Shareholder Ownership Skewed Towards Insiders?
Jan 14
Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013) Is Yielding 1.5% - But Is It A Buy?
Dec 23Dr. Sulaiman Al Habib Medical Services Group Company's (TADAWUL:4013) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Nov 27Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 15,646 | 3,235 | 2,325 | 4,260 | 9 |
| 12/31/2025 | 13,356 | 2,676 | 1,407 | 3,564 | 9 |
| 12/31/2024 | 11,116 | 2,232 | -278 | 3,049 | 8 |
| 6/30/2024 | 10,024 | 2,176 | -1,046 | 3,031 | N/A |
| 3/31/2024 | 9,723 | 2,108 | -758 | 3,291 | N/A |
| 12/31/2023 | 9,508 | 2,046 | -253 | 3,244 | N/A |
| 9/30/2023 | 9,276 | 1,962 | 60 | 3,072 | N/A |
| 6/30/2023 | 8,885 | 1,838 | 509 | 2,789 | N/A |
| 3/31/2023 | 8,627 | 1,750 | 1,219 | 2,932 | N/A |
| 12/31/2022 | 8,311 | 1,651 | 1,330 | 2,844 | N/A |
| 9/30/2022 | 8,025 | 1,593 | 838 | 2,411 | N/A |
| 6/30/2022 | 7,809 | 1,521 | 956 | 2,254 | N/A |
| 3/31/2022 | 7,547 | 1,448 | 1,067 | 2,419 | N/A |
| 12/31/2021 | 7,250 | 1,377 | 929 | 2,183 | N/A |
| 9/30/2021 | 6,974 | 1,311 | 1,156 | 2,441 | N/A |
| 6/30/2021 | 6,761 | 1,261 | 1,120 | 2,170 | N/A |
| 3/31/2021 | 6,213 | 1,128 | 1,219 | 2,183 | N/A |
| 12/31/2020 | 5,862 | 1,055 | 1,420 | 2,234 | N/A |
| 9/30/2020 | 5,575 | 1,008 | 1,219 | 1,871 | N/A |
| 6/30/2020 | 5,178 | 907 | 1,030 | 1,743 | N/A |
| 3/31/2020 | 5,132 | 883 | 503 | 1,155 | N/A |
| 12/31/2019 | 5,016 | 870 | 326 | 1,059 | N/A |
| 9/30/2019 | 4,816 | 825 | 843 | 1,549 | N/A |
| 6/30/2019 | 4,735 | 835 | 753 | 1,539 | N/A |
| 3/31/2019 | 4,646 | 819 | 1,005 | 1,760 | N/A |
| 12/31/2018 | 4,588 | 801 | 789 | 1,447 | N/A |
| 12/31/2017 | 4,687 | 658 | N/A | 1,058 | N/A |
| 12/31/2016 | 4,868 | 1,010 | N/A | 900 | N/A |
| 12/31/2015 | 5,123 | 1,329 | N/A | 922 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei 4013 ( 14.9% per jaar) ligt boven de spaarquote ( 14.5% ).
Winst versus markt: De winst van 4013 ( 14.9% per jaar) zal naar verwachting sneller groeien dan de SA markt ( 7.3% per jaar).
Hoge groeiwinsten: De winst van 4013 zal naar verwachting groeien, maar niet aanzienlijk.
Omzet versus markt: De omzet van 4013 ( 14.6% per jaar) zal naar verwachting sneller groeien dan de markt SA ( 1.2% per jaar).
Hoge groei-inkomsten: De omzet van 4013 ( 14.6% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen 4013 zal naar verwachting over 3 jaar hoog zijn ( 39.1 %)